<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065336</url>
  </required_header>
  <id_info>
    <org_study_id>Heparc-2001</org_study_id>
    <nct_id>NCT02065336</nct_id>
  </id_info>
  <brief_title>Study of ARC-520 in Patients With Chronic Hepatitis B Virus</brief_title>
  <official_title>A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ARC-520 in combination with entecavir is
      effective in the treatment of patients with Chronic Hepatitis B Virus (HBV) Infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment with ARC-520 for injection is expected to reduce all HBV proteins and replicative
      intermediates via RNA interference. The magnitude of the reduction and duration of effect
      will depend on the dose. Since to date ARC-520 has not been administered to patients with
      chronic HBV infection, the effective therapeutic dose in patients with chronic HBV infection
      is unknown. This study is designed to assess the antiviral activity of ARC-520, especially
      it's effect on HBsAg, in patients with chronic HBV infection at different dose levels.

      This is a multicenter, randomized, double-blind, placebo-controlled, single dose escalation
      study of ARC 520 in combination with entecavir administered to patients with HBeAg negative
      (Cohorts 1 through 4) or HBeAg positive (Cohort 5) immune active, chronic HBV infection,
      followed by a two-dose open-label cohort (Cohort 6), three open label single dose cohorts in
      treatment naïve patients (Cohorts 7, 11 and 12) and an open label multi-dose extension study
      (cohorts 8, 9, 10). Cohort 6 will investigate ARC-520 in combination with entecavir
      administered in two doses to patients with HBeAg positive immune active chronic HBV
      infection. Cohorts 7, 11 and 12 will enroll treatment naïve patients. Cohort 8 will only
      enroll subjects previously completing cohorts 1-4. Cohort 9 will only enroll subjects
      previously completing cohort 5 or 6. Cohort 10 will only enroll subjects previously
      completing cohort 7.

      Patients will undergo the following evaluations at regular intervals during the study:
      medical history, physical examinations, vital sign measurements (blood pressure, heart rate,
      respiratory rate, and temperature), weight, adverse events (AEs), 12-lead electrocardiograms
      (ECGs), concomitant medication, blood sample collection for hematology, coagulation,
      chemistry, pharmacokinetic (PK) and exploratory pharmacodynamic (PD) measures, urinalysis,
      HBV serology, HBV genotyping and sequencing, FSH testing and pregnancy testing for females of
      childbearing potential. Clinically significant changes including AEs will be followed until
      resolution, until the condition stabilizes, until the event is otherwise explained, or until
      the patient is lost to follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision to discontinue trial
  </why_stopped>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in quantitative hepatitis B surface antigen (HBsAG) as a measure of efficacy</measure>
    <time_frame>Through Day 85 (Cohorts 1-7, 11, 12); Through 24 weeks post last dose (Cohorts 8-10)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and frequency of adverse events as a measure of safety and tolerability</measure>
    <time_frame>Through Day 85 (Cohorts 1-7, 11, 12); Through 24 weeks post last dose (Cohorts 8-10)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Immunoglobulin E (IgE) as a measure of allergenicity of ARC-520</measure>
    <time_frame>Day 29 and Day 85</time_frame>
    <description>Cohorts 1-7 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on entecavir plasma trough concentration</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Cohorts 1-7 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520: AUC0-24 (Cohorts 1-5 only)</measure>
    <time_frame>Through 48 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520: AUClast (Cohorts 1-5 only)</measure>
    <time_frame>Through 48 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to the last quantifiable plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520: AUCinf: Change over time (Cohorts 1-5 only)</measure>
    <time_frame>Through 48 hours post dose</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520: Cmax: Change over time (Cohorts 1-5 only)</measure>
    <time_frame>Through 48 hours post dose</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520: CL: Change over time (Cohorts 1-5 only)</measure>
    <time_frame>Through 48 hours post dose</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520: V: Change over time (Cohorts 1-5 only)</measure>
    <time_frame>Through 48 hours post dose</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520: kel: Change over time (Cohorts 1-5 only)</measure>
    <time_frame>Through 48 hours post dose</time_frame>
    <description>Terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ARC-520: t1/2: Change over time (Cohorts 1-5 only)</measure>
    <time_frame>Through 48 hours post dose</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>ARC-520 Cohorts 1-5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, IV ARC-520, 1.0, 2.0, 3.0 or 4.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Normal Saline Cohorts 1-5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose, IV normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two doses, IV ARC-520, 2.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, IV ARC-520, 4.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ARC-520, 4.0 mg/kg Q4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ARC-520, 4.0 mg/kg Q6 weeks or Q8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 10, tx naive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV ARC-520, 4.0 mg/kg Q4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, IV ARC-520, 5.0 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARC-520 Cohort 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose, IV ARC-520, 6.0 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARC-520</intervention_name>
    <arm_group_label>ARC-520 Cohorts 1-5</arm_group_label>
    <arm_group_label>ARC-520 Cohort 6</arm_group_label>
    <arm_group_label>ARC-520 Cohort 7</arm_group_label>
    <arm_group_label>ARC-520 Cohort 8</arm_group_label>
    <arm_group_label>ARC-520 Cohort 9</arm_group_label>
    <arm_group_label>ARC-520 Cohort 10, tx naive</arm_group_label>
    <arm_group_label>ARC-520 Cohort 11</arm_group_label>
    <arm_group_label>ARC-520 Cohort 12</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo Normal Saline Cohorts 1-5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of HBeAg negative and immune active chronic HBV infection (Cohorts 1-4, 8)

          -  Diagnosis of HBeAg positive and immune active chronic HBV infection (Cohorts 5-6, 9)

          -  Diagnosis of HBeAg negative or HBeAg positive and immune active or tolerant chronic
             HBV infection (Cohorts 7, 10, 11 &amp; 12)

          -  Patients with &gt; 6 months of continuous, 0.5 mg/day oral entecavir, and a willingness
             to continue taking entecavir throughout the study (Cohorts 1-6, 8-9).

          -  Patients naive to entecavir (never on entecavir or on entecavir &lt;30 days prior to
             screening) and a willingness to take entecavir and willingness to continue taking
             entecavir throughout the study (Cohorts 7, 11 &amp; 12).

        Key Exclusion Criteria:

          -  Female patients that have a positive pregnancy test or are lactating.

          -  Acute signs of hepatitis/other infection (eg, moderate fever, jaundice, nausea,
             vomiting, and abdominal pain) evident within 4 weeks of screening and/or at the
             screening examination.

          -  Patients with antiviral therapy other than entecavir within 3 months of screening or
             prior treatment with interferon or a toll receptor agonist in the last 5 years.

          -  Use within the last 6 months or an anticipated requirement for anticoagulants,
             corticosteroids, immunomodulators, or immunosuppressants.

          -  Has any history of autoimmune disease especially autoimmune hepatitis.

          -  Has human immunodeficiency virus (HIV) infection, as shown by the presence of anti-HIV
             antibody (sero-positive).

          -  Is sero-positive for hepatitis C virus (HCV), and/or a history of delta virus
             hepatitis.

          -  Has a history of allergy to bee venom or history of hypersensitivity reaction
             requiring an emergency visit to a physician or hospital and/or requirement for
             treatment with steroids and/or epinephrine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Given, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Arrowhead Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2014</study_first_submitted>
  <study_first_submitted_qc>February 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV</keyword>
  <keyword>Hepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 10, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

